Gene and Cell Therapy Group
Executive Assistant to Prof. Robin Ali and Department of Genetics
- Tel: +44 (0)207 608 4023
- Email: email@example.com
Department Coordinator & Acting Personal Assistant to Prof. Robin Ali and Department of Genetics
- Tel: +44 (0)207 608 4023
- Email: firstname.lastname@example.org
Dr. Andi Skilton
Ocular Gene and Cell Therapy Communications Manager
James Bainbridge MA PhD FRCOphth
As a surgeon-scientist, Professor Bainbridge aims to help protect and promote healthy eyesight by developing effective new treatments for diseases of the retina.
Professor of Retinal Studies, UCL Institute of Ophthalmology
NIHR Research Professor, NIHR Biomedical Research Centre for Ophthalmology
Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust
His programme of research extends from the laboratory investigation of mechanisms of retinal disease to clinical trials of new medical and surgical interventions.
|2012-||NIHR Research Professor,||NIHR Biomedical Research Centre for Ophthalmology|
|2011-||Professor of Retinal Studies||UCL Institute of Ophthalmology|
|2007-||Faculty Investigator||National Institute for Health Research|
|2007-||Diabetes Theme Leader||NIHR Biomedical Research Centre|
|2005-||Honorary Consultant Ophthalmologist||Moorfields Eye Hospital|
|2005-10||Wellcome Advanced Fellow||UCL Institute of Ophthalmology, London|
|2004-5||Clinical Fellow in Vitreoretinal Surgery||Moorfields Eye Hospital, London|
|2003-4||Specialist Registrar in Ophthalmology||Moorfields Eye Hospital, London|
|2000-3||Wellcome Research Training Fellow||UCL Institute of Ophthalmology|
|1999-00||Specialist Registrar in Ophthalmology||Moorfields Eye Hospital, London|
|1998-9||Specialist Registrar in Ophthalmology||Charing Cross Hospital, London|
|1997-8||Specialist Registrar in Ophthalmology||North Middlesex Hospital, London|
|1996-7||Senior House Officer in Ophthalmology||Royal Eye Unit, Kingston|
|1995-6||Senior House Officer in Ophthalmology||St. George's Hospital, London|
|1994-5||Senior House Officer in Ophthalmology||Frimley Park Hospital, Surrey|
|1994-5||Senior House Officer in Neurosurgery||The National Hospital, Queen Sq, London|
|1993-4||SHO in Accident and Emergency||St. Mary's Hospital, London|
|1993||House Physician to Prof H Thomas||St. Mary's Hospital, London|
|1992-3||House Surgeon||St. Mary's Hospital, London|
|1989-92||St. Mary's Hospital Medical School, London|
|1986-89||King's College, Cambridge|
|1979-86||Queen Elizabeth's School, Faversham, Kent|
|1996||FRCOphth||Royal College of Ophthalmologists|
|1992||MB BChir||University of Cambridge|
|1989||BA||University of Cambridge|
Awards and Distinctions
|2009||Foundation Fighting Blindness Board of Directors’ Award|
|2008||The Fincham Medal, Worshipful Company of Spectacle Makers|
|2004||Moorfields Research Medal|
|2003||Academy of Medical Sciences Award for Ophthalmology|
|2002||Academy of Medical Sciences Young Investigator Award Finalist|
|2001||The Foulds Trophy, Royal College of Ophthalmologists|
|1991||Thomas Keeping Award, University of Cambridge|
|1991||Mary Euphrasia Moseley Exhibition, University of Cambridge|
|2009-||Candidate Member, Club Jules Gonin|
|2008-||Member of the American Academy of Ophthalmology|
|2003-||Member of the Medical Research Society|
|2003-||Member of the British Society for Gene and Cell Therapy|
|1998-||Member of the Association for Research in Vision and Ophthalmology|
|1996-||Fellow of the Royal College of Ophthalmologists|
|1996-||Member of the European Society of Ophthalmology|
Moorfields Eye Hospital
162 City Road London EC1V 2PD
Contact: Brenda Aveyard
Tel 020 7253 3411 Ext. 2576
Moorfields Eye Hospital: John Saunders Suite
9-11 Bath Street London EC1V 9LF
Contact: Carolyn Watson
Tel 020 7253 2640
Fax 020 7566 2608
How to reach Moorfields
Underground: Old Street - Northern Line
From Old Street Station leave by Exit 8 and follow the green line on the pavement.
The main entrance to Moorfields Eye Hospital in on the left.
Private and overseas patients should continue along Cayton Street and turn right into Bath Street: the John Saunders Suite is the first entrance on the right.
205, 43, 214 (City Road)
141, 271, 65 (East Road)
245, 55 (Old Street)
393 (Shepherdess Walk)
The nearest mainline stations are Euston and Kings Cross; to reach Moorfields take the Undergound Northern Line to Old Street, a bus (205 from Euston, 214 from Kings Cross) or a taxi.
Professor Bainbridge’s research group is based in the Gene and Cell Therapy Group of the Department of Genetics, UCL Institute of Ophthalmology, and works in close collaboration with Professor Robin Ali FMedSci.
Our aim is to protect and promote healthy eyesight by research to develop effective new treatments for disorders of the retina. These include inherited disorders, age-related macular degeneration and diabetes. Our research projects extend from the laboratory investigation of basic mechanisms of disease, through experimental models to the preclinical development of novel molecular therapies and clinical trials.
Retinal disease is a major research priority
Disorders of the retina are responsible for sight loss in the 2/3 of people with eye disease in the UK and are a priority target for Moorfields’ research strategy. Age-related macular degneration (AMD) affects 1.5 million people today and is likely to affect 1.8 million by 2020. Diabetic retinopathy affects ¾ million now and is expected to affect 1 million in 2020. Retinal disease in childhood is another key priority because it currently causes lifelong disability but may be particularly amenable to novel interventions; successful proof-of-principle for new treatments in inherited childhood blindness is expected to accelerate their application to common retinal disorders of aging.
A new era of molecular therapy in retinal disease
Physical treatments, including laser or standard surgical techniques, have been the mainstay for management of retinal disease for decades. However, these approaches are effective for only a minority of conditions and until recently the majority of blinding retinal diseases were essentially untreatable. Systematic research in recent years has led to an improved understanding of the causes of common blinding retinal disease. This is now enabling the identification of targets and opportunities for therapy. The development of rationally-designed biological, gene and cell therapies, together with rapid advances in technology for the diagnosis of retinal disease and its progression have introduced a new era of intervention. The development of targeted therapeutic antibodies, for example, is having a major impact on the outlook for people with macular degeneration and diabetes. At Moorfields we have demonstrated proof-of-principle that gene therapy can improve sight in childhood blindness and are translating preclinical success in cell transplantation into new interventions for people with retinal degenerations.
The retina is uniquely suited to targeted intervention
Ocular tissues can be targeted precisely using modern microsurgical techniques. Furthermore, we are able to measure the impact of intervention in the living human eye non-invasively by optical imaging at an extraordinary level of cellular and molecular detail. These features account in large part for the recent successful proof-of-concept of new molecular interventions for retinal disease that have demonstrated remarkable progress in ophthalmology. Moreover, the eye is now widely recognised for its value in investigating pathological neuro-degenerative and microvascular disease, and as an important model system for developing novel interventions.
Professor Bainbridge’s research group is based in the Department of Genetics, UCL Institute of Ophthalmology www.ucl.ac.uk/ioo and works in close collaboration with Professor Robin Ali FMedSci
|Ranjan Rajendram MD MRCOphth||NIHR|
|Neuroglobin in retinal health and disease|
|Scott Robbie MRCOphth||NIHR|
|Macrophages in retinal ageing and angiogenesis|
Postdoctoral Research Assistant
|Tiina Sepp PhD||NIHR|
|Therapeutic antibodies for retinal vascular disease|
Clinical Research Fellows
|Clemens Lange MD PhD||NIHR|
|Retinal oxygen and molecular mediators of angiogenesis|
|Venki Sundaran MRCOphth||
|Clinical trial of gene therapy for retinal degeneration, MD(Res)|
|Oliver Comyn MRCOphth||NIHR/Novartis|
|Ranibizumab in diabetic vitrectomy, MD(Res)|
Gene Therapy Clinical Trials Administrator
Sneha Haria MRes
Previous Research Fellows
|Freya Mowat MRCVS PhD||The Wellcome Trust|
|Molecular and cellular approaches to ocular angiogenesis||Currently Post-doc Michigan, USA|
|Kamaljit Balaggan MRCOphth PhD||Oxford Biomedica|
|Gene therapy for choroidal neovascularisation||Currently Retina Fellow, Moorfields|
|Scott Robbie MRCOphth||NIHR|
|Role of macrophages in retinal aging and disease||Currently NIHR Clinical Lecturer|
Previous BSc Students
||BSc awarded 2010|
|DDAH2 in retinal and choroidal neovascularisation|
Previous Visiting Fellows
|Harry Bradshaw FRANZCO|
|Imaging neuroglobin in the living eye|
|Akiko Kogure, MD|
|Oxygen in retinal detachment|
|Eric Lindstedt MD|
|Oxygen in retinal detachment|
|Pilar Villacampa PhD|
|Ischaemia-induced retinal neovascularisation|
Posterior vitreous detachment
Posterior vitreous detachment (PVD) is a common condition that affects the majority of people with increasing age and is normally harmless.
The vitreous is an optically clear, gel-like tissue that fills much of the eye. In youth the vitreous is firmly applied to the retina, which is a sheet of light-sensitive nerves essential for sight.
With increasing age the vitreous typically becomes less cohesive and peels away from the retina. The process of vitreous detachment can proceed rapidly or very slowly. Many people experience no symptoms.
Debris within vitreous that has detached from the retina floats in front of the retina casting shadows that are perceived as ‘floaters’. Floaters can take many forms including ‘flies’, lines, circles, clouds or ‘cobwebs’. Floaters can sometimes interfere intermittently with the ability to read clearly. Floaters can persist for some months but generally become less noticeable given time.
As the vitreous detaches from the retina, mechanical stimulation of light-sensitive nerves is perceived as flashing lights (‘photopsia’). Flashing lights typically resolve once the process of vitreous detachment is complete.
Retinal tears and retinal detachment
Occasionally, traction of the vitreous at points of firm attachment to the retina can cause tears in the retina. Even small retinal tears can bleed into the vitreous, causing dense floaters, and can allow fluid in the vitreous to leak behind the retina causing detachment of the retina that threatens sight. Retinal detachment is typically perceived as a dense ‘shadow’ or ‘curtain’ that progressively obscures the sight in one eye.
The onset of new floaters, flashing lights or loss of vision justifies prompt specialist assessment to exclude sight-threatening retinal tears or detachment.
Treatment of retinal tears and retinal detachment
If recognised promptly, retinal tears can often be treated effectively using laser alone. Retinal detachment can usually be repaired effectively by surgery, which typically involves removal of the vitreous (vitrectomy), laser treatment to seal the tear, and injection of a bubble of temporary gas to keep the retina in place while it heals.
Vitrectomy surgery is keyhole surgery involving removal of the vitreous gel to enable repair of retinal disorders including tears and detachment. The vitreous is replaced by fluid.
Vitrectomy surgery can be performed using local anaesthetic, sedation or general anaesthetic. Daycase surgery is routine but an overnight stay in hospital can be convenient for some people.
A bubble of gas may be injected to support the retina while it heals. A specific position may be advised to make the best use of the bubble. The presence of gas obscures sight but, as the bubble is absorbed during a period of 2 to 6 weeks, sight can be expected to improve. Normal activities and air travel can be safely resumed once the gas bubble has been fully absorbed.
Discomfort and redness are common during recovery, especially if stitches have been used. Eyedrops are routinely prescribed for up to 4 weeks to help minimise inflammation and prevent infection. An eye shield may be used at night for comfort if desired.
Sight and comfort can be expected to improve progressively. Most people return to the clinic for routine review 1-2 weeks following vitrectomy surgery.
Deterioration in sight or comfort following surgery justifies urgent specialist advice.
UCL Institute of Ophthalmology
Professor Robin Ali
Professor Fred Fitzke
Professor John Greenwood
Professor Graham Holder
Professor Phil Luthert
Mr Michel Michaelides
Professor Steve Moss
Professor Tony Moore
Dr Rachel Pearson
Professor Gary Rubin
Professor Christiana Ruhrberg
Professor Dave Shima
Professor Andrew Stockman
Mr Andrew Webster
UCL Division of Medicine
Professor Patrick Maxwell
UCL Institute of Child Health
Professor Jane Sowden
UCL Dept Engineering
Professor Nick Tyler
Imperial College London
Dr James Leiper
University of Bristol
Professor Andrew Dick
Professor Dave Bates
Professor Steve Harper
Michigan State University
|Professor Simon Petersen-Jones|
Page last modified on 23 jan 13 10:24